UNSPSC 51411707: Papaverine or papaverinum

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DAA13NKG2Q, chemically known as 6,7,3,4-tetramethoxy-1-benzylisoquinoline hydrochloride but generally known as papaverine, which bears US NIH Compound Identifier 4680. European Medicines Agency schedules Papaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14760MIG.

World Health Organization schedules papaverine in its Anatomical Therapeutic Chemical (ATC) Classification. Papaverine or papaverinum bears US NLM identifiers UMLS ID C0030350 and NCI Concept Code C726. SMILES: O(c1cc2c(nccc2cc1OC)Cc1cc(OC)c(OC)cc1)C.

UNSPSC 51411707 Papaverine or papaverinum, a Commodity code, sees limited direct solicitation activity in state and local procurement; however, the code sits within the broader pharmaceutical supply chain being purchased by municipalities, state health agencies, and cooperative purchasing alliances for emergency medical services, pharmacy benefit programs, and institutional healthcare operations. State and local governments procure papaverine and related pharmaceutical compounds as part of larger advanced life support medication contracts, pharmacy formulary agreements, and generic drug supply arrangements. The issuing bodies include city fire and rescue departments (like Tampa Fire Rescue), state health and human services commissions (like Texas HHS), and multistate cooperative purchasing organizations (like the Minnesota Multistate Cooperative Purchasing Alliance). Work solicited under this code ranges from direct medication supply for emergency responder use to participation in statewide or multistate generic pharmaceutical frameworks that establish pricing and distribution through authorized wholesalers.

Recent activity shows the code embedded within broader pharmaceutical procurement initiatives rather than as a standalone line item. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications for Tampa Fire Rescue in Hillsborough County, Florida—a sealed-bid procurement with response due April 8, 2026, estimated at $40,000 with a one-year term and optional renewals; while papaverine was not explicitly named, the solicitation illustrates the municipal fire-rescue medication supply chain. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, signaling state-level interest in pharmaceutical supply chain restructuring. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026. Geographic activity centers on Texas, Florida, and the Upper Midwest multistate cooperative region, with limited visibility into whether papaverine specifically appears in current award schedules.